Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 173

1.

Suppression of Human Platelet Activation via Integrin αIIbβ3 Outside-In Independent Signal and Reduction of the Mortality in Pulmonary Thrombosis by Auraptene.

Hsia CW, Tsai CL, Sheu JR, Lu WJ, Hsia CH, Velusamy M, Jayakumar T, Li JY.

Int J Mol Sci. 2019 Nov 8;20(22). pii: E5585. doi: 10.3390/ijms20225585.

2.

Thrombin Upregulates PAI-1 and Mesothelial-Mesenchymal Transition Through PAR-1 and Contributes to Tuberculous Pleural Fibrosis.

Hsieh CY, Sheu JR, Yang CH, Chen WL, Tsai JH, Chung CL.

Int J Mol Sci. 2019 Oct 13;20(20). pii: E5076. doi: 10.3390/ijms20205076.

3.

A Critical Period for the Development of Schizophrenia-Like Pathology by Aberrant Postnatal Neurogenesis.

Sheu JR, Hsieh CY, Jayakumar T, Tseng MF, Lee HN, Huang SW, Manubolu M, Yang CH.

Front Neurosci. 2019 Jun 18;13:635. doi: 10.3389/fnins.2019.00635. eCollection 2019.

4.

Esculetin, a Coumarin Derivative, Prevents Thrombosis: Inhibitory Signaling on PLCγ2-PKC-AKT Activation in Human Platelets.

Hsia CW, Lin KC, Lee TY, Hsia CH, Chou DS, Jayakumar T, Velusamy M, Chang CC, Sheu JR.

Int J Mol Sci. 2019 Jun 3;20(11). pii: E2731. doi: 10.3390/ijms20112731.

5.

[Corrigendum] Novel iridium (III)‑derived organometallic compound for the inhibition of human platelet activation.

Shyu KG, Velusamy M, Hsia CW, Yang CH, Hsia CH, Chou DS, Jayakumar T, Sheu JR, Li JY.

Int J Mol Med. 2019 Jul;44(1):357. doi: 10.3892/ijmm.2019.4177. Epub 2019 Apr 30.

6.

HDAC6 dysfunction contributes to impaired maturation of adult neurogenesis in vivo: vital role on functional recovery after ischemic stroke.

Sheu JR, Hsieh CY, Jayakumar T, Lin GY, Lee HN, Huang SW, Yang CH.

J Biomed Sci. 2019 Apr 18;26(1):27. doi: 10.1186/s12929-019-0521-1.

7.

Analysis of Titin in Red and White Muscles: Crucial Role on Muscle Contractions Using a Fish Model.

Wu MP, Chang NC, Chung CL, Chiu WC, Hsu CC, Chen HM, Sheu JR, Jayakumar T, Chou DS, Fong TH.

Biomed Res Int. 2018 Nov 18;2018:5816875. doi: 10.1155/2018/5816875. eCollection 2018.

8.

Molecular Pharmacology and Pathology of Strokes.

Sheu JR.

Int J Mol Sci. 2018 Dec 18;19(12). pii: E4103. doi: 10.3390/ijms19124103.

9.

New therapeutic strategy of hinokitiol in haemorrhagic shock-induced liver injury.

Lu WJ, Lin KH, Tseng MF, Yuan KC, Huang HC, Sheu JR, Chen RJ.

J Cell Mol Med. 2019 Mar;23(3):1723-1734. doi: 10.1111/jcmm.14070. Epub 2018 Dec 8.

10.
11.

Structure⁻Activity Relationship Study of Newly Synthesized Iridium-III Complexes as Potential Series for Treating Thrombotic Diseases.

Yang CH, Hsia CW, Jayakumar T, Sheu JR, Hsia CH, Khamrang T, Chen YJ, Manubolu M, Chang Y.

Int J Mol Sci. 2018 Nov 19;19(11). pii: E3641. doi: 10.3390/ijms19113641.

12.

An Antithrombotic Strategy by Targeting Phospholipase D in Human Platelets.

Lu WJ, Chung CL, Chen RJ, Huang LT, Lien LM, Chang CC, Lin KH, Sheu JR.

J Clin Med. 2018 Nov 14;7(11). pii: E440. doi: 10.3390/jcm7110440.

13.

Novel Therapeutic Agent against Platelet Activation In Vitro and Arterial Thrombosis In Vivo by Morin Hydrate.

Hsia CW, Wu MP, Velusamy M, Hsia CH, Chou DS, Tsai CL, Hsu CY, Jayakumar T, Chung CL, Sheu JR.

Int J Mol Sci. 2018 Aug 13;19(8). pii: E2386. doi: 10.3390/ijms19082386.

14.

Possible Molecular Targets of Novel Ruthenium Complexes in Antiplatelet Therapy.

Jayakumar T, Hsu CY, Khamrang T, Hsia CH, Hsia CW, Manubolu M, Sheu JR.

Int J Mol Sci. 2018 Jun 20;19(6). pii: E1818. doi: 10.3390/ijms19061818. Review.

15.

Ir-6: A Novel Iridium (III) Organometallic Derivative for Inhibition of Human Platelet Activation.

Shyu RS, Khamrang T, Sheu JR, Hsia CW, Velusamy M, Hsia CH, Chou DS, Chang CC.

Bioinorg Chem Appl. 2018 May 2;2018:8291393. doi: 10.1155/2018/8291393. eCollection 2018.

16.

Hinokitiol Inhibits Migration of A549 Lung Cancer Cells via Suppression of MMPs and Induction of Antioxidant Enzymes and Apoptosis.

Jayakumar T, Liu CH, Wu GY, Lee TY, Manubolu M, Hsieh CY, Yang CH, Sheu JR.

Int J Mol Sci. 2018 Mar 22;19(4). pii: E939. doi: 10.3390/ijms19040939.

17.

Structure-Antiplatelet Activity Relationships of Novel Ruthenium (II) Complexes: Investigation of Its Molecular Targets.

Hsia CH, Jayakumar T, Sheu JR, Tsao SY, Velusamy M, Hsia CW, Chou DS, Chang CC, Chung CL, Khamrang T, Lin KC.

Molecules. 2018 Feb 22;23(2). pii: E477. doi: 10.3390/molecules23020477.

18.

Novel iridium (III)‑derived organometallic compound for the inhibition of human platelet activation.

Shyu KG, Velusamy M, Hsia CW, Yang CH, Hsia CH, Chou DS, Jayakumar T, Sheu JR, Li JY.

Int J Mol Med. 2018 May;41(5):2589-2600. doi: 10.3892/ijmm.2018.3472. Epub 2018 Feb 7. Erratum in: Int J Mol Med. 2019 Jul;44(1):357.

19.

Norcantharidin, a clinical used chemotherapeutic agent, acts as a powerful inhibitor by interfering with fibrinogen-integrin αIIb β3 binding in human platelets.

Hsia CH, Lu WJ, Lin KH, Chou DS, Geraldine P, Jayakuma T, Chang NC, Sheu JR.

J Cell Mol Med. 2018 Apr;22(4):2142-2152. doi: 10.1111/jcmm.13488. Epub 2018 Jan 25.

20.

CME-1, a novel polysaccharide, suppresses iNOS expression in lipopolysaccharide-stimulated macrophages through ceramide-initiated protein phosphatase 2A activation.

Sheu JR, Chen ZC, Hsu MJ, Wang SH, Jung KW, Wu WF, Pan SH, Teng RD, Yang CH, Hsieh CY.

J Cell Mol Med. 2018 Feb;22(2):999-1013. doi: 10.1111/jcmm.13424. Epub 2017 Dec 7.

Supplemental Content

Loading ...
Support Center